EXAS Exact Sciences Corporation
USHealthcareAs of 2026-03-23 09:30
Why EXAS matters now
Exact Sciences Corporation (EXAS) is a US stock in Healthcare. The latest InvestLog snapshot shows $104.91 with +0.00% on the session and $20.03B in market capitalization; recent performance reads 1-month +0.00% and YTD +3.30%.
The latest financial table shown here is Q4 2025, with revenue of $878.4M, net income of $-86.0M, and EPS of $-0.45. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 1.8%.
The latest indexable market news headline is "Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $105.00; recent insider activity includes Trigg Leslie filing D-Return; recent congressional disclosure data includes Kevin Hern Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.29
P/S
6.17
EV/EBITDA
397.39
DCF Value
$76.77
FCF Yield
1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.7%
Operating Margin
-6.2%
Net Margin
-6.4%
ROE
-8.5%
ROA
-3.5%
ROIC
-4.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $878.4M | $-86.0M | $-0.45 |
| FY 2025 | $3.25B | $-207.9M | $-1.10 |
| Q3 2025 | $850.7M | $-19.6M | $-0.10 |
| Q2 2025 | $811.1M | $-1.2M | $-0.01 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$105.00
Target (Median)
$105.00
Target Range
$105.00 - $105.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.44
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.